People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NiKang Therapeutics, Inc. | — | Biotechnology | Series D+ | $200.0M | $6.2B | 2021 |
| AnBio Therapeutics Ltd. | — | Biotechnology | Series C | $60.9M | $1.6B | 2021 |
Ting Jia at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ting Jia on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Roderick Wong | 1 | 4 |
| Gary Yeung | 1 | 2 |
| Wei Xu | 1 | 2 |
| Zhengbin Yao | 1 | 2 |
| Lihua Zheng | 1 | 1 |
| Junyuan Wang | 1 | 1 |
| Zhengwei Zhu | 1 | 1 |
| Xiaohang (Tony) Tong | 1 | 1 |
| Bing Yan | 1 | 1 |
| Hong (Kelsey) Chen | 1 | 1 |
| Zhenhai Gao | 1 | 1 |
| Wei Fu | 1 | 1 |
| Sean Cao | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.